Drug intelligence / Profile preview

NXC680

Development stage: Unknown
Lead developer: NEXTGEN Bioscience
Modality: Small Molecules
Administration: Oral

Overview

NXC680 is a small molecule autotaxin (ATX) inhibitor being developed by NEXTGEN Bioscience for the treatment of idiopathic pulmonary fibrosis (IPF). Autotaxin is a secreted enzyme responsible for the production of lysophosphatidic acid (LPA), a bioactive lipid that promotes fibroblast activation, proliferation, and migration, which are key drivers of tissue fibrosis. By inhibiting ATX, NXC680 reduces LPA levels, thereby potentially slowing or halting the progression of fibrotic lung disease. The drug is currently in Phase 1 clinical development.

Targets

ENPP2 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 2)

Beyond the preview

Go deeper on NXC680.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NXC680.

Explore the full profile